Given that immunogenicity to biologics may contribute to IBD treatment failure, the study authors sought to determine the rate of ADA formation to individual biologic agents.
Titers of anti-S IgG lower for patients with chronic inflammatory disease receiving glucocorticoids or B-cell depletion therapy
Antibody concentrations lower in infliximab-treated individuals with IBD receiving single dose of BNT162b2 or ChAdOx1 nCoV-19 vaccine
Patients with IBD were compared to control groups without IBD, which included 14 completely vaccinated healthcare workers and 29 vaccinated healthy volunteers.
Significant improvements in both clinical symptoms (ie, abdominal pain, general well-being, nausea, diarrhea, and decreased appetite) as well as QoL scores were observed with cannabinoids.
23andMe, a consumer genetics company, has licensed its first drug compound to Almirall, a global pharmaceutical company.
Trends in the utilization of emergency department (ED) care and hospitalization among patients with inflammatory bowel disease (IBD) were investigated in a new study.
The safety profiles of various IV iron products were compared in a study involving patients with inflammatory bowel disease IBD being treated for iron deficiency anemia.
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
In older patients with inflammatory bowel disease (IBD), tumor necrosis factor alpha antagonist (anti-TNF) therapy and vedolizumab (an integrin receptor antagonist) were found to be comparable with regard to both safety and effectiveness, according to a study published in Alimentary Pharmacology & Therapeutics.
